Financial insights of IMCR

MyFinsight

For the quarter ending 2025-09-30, IMCR made $103,693K in revenue. -$3,569K in net income. Net profit margin of -3.44%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Income Statement	2025-09-30	2025-06-30	2025-03-31	2024-09-30
Total revenue	103,693	97,964	93,881	80,248
Cost of revenue from sale of therapies	513	1,040	831	448
Research and development expense	70,572	69,008	56,468	52,770
Selling, general and administrative expense	39,779	42,791	40,198	35,532
Loss from operations	-7,171	-14,875	-3,616	-8,502
Interest income	4,123	4,271	4,176	5,960
Interest expense	3,043	3,045	3,025	4,290
Foreign currency gain	1,333	-738	3,080	3,963
Other income, net	5,062	4,693	5,469	8,962
Net income (loss) before income taxes	304	-9,694	6,084	6,093
Income tax (expense) benefit	481	606	1,061	-2,643
Net (loss) income	-177	-10,300	5,023	8,736
Exchange differences on translation of foreign operations	-3,392	6,476	673	3,247
Total comprehensive (loss) income	-3,569	-3,824	5,696	11,983

Basic net (loss) income per share (in usd per share)	0	-0.2	0.1	0.17
Basic weighted-average number of shares outstanding (in shares)	50,403,717	50,294,205	50,086,684	50,021,939
Diluted net (loss) income per share (in usd per share)	0	-0.2	0.1	0.17
Diluted weighted-average number of shares outstanding (in shares)	50,403,717	50,294,205	51,949,798	52,808,434